The size of the Asia Pacific Tissue diagnostics Market has been calculated at USD 730 million in 2020 and estimated to be growing at a CAGR of 7.2%, to reach USD 1040 million by 2025.
Tissue-based diagnostic tests are performed to screen, diagnose, and monitor the response of cancer patients to therapy. The scope of the tissue diagnostics market includes major technologies like ISH, IHC, digital pathology and workflow, and special staining, and products like instruments and consumables that are used to determine medical information for the diagnosis of diseases or conditions.
The tissue Diagnosis technique is one of the gold standards set in cancer diagnosis and is the crucial driver in the market. The tissue-based diagnosis technique helps to determine the cause and effect of the disease in a patient. Due to the unhealthy lifestyles of the population, the rate of cancer incidences is growing each year, driving the market for tissue-based diagnosis. A cancer diagnosis at early stages and treatment will lead to better chances of survival. The diagnostics market will show significant growth by forcing labs to increase efficiency in the diagnosis process to maximize patients' health security. The limited customer base for tissue diagnostics, limited budget issues, and regulatory framework issues are the factors hindering the market's growth.
This research report on the APAC Tissue Diagnostics Market has been segmented and sub-segmented into the following categories:
By Product Type:
By Application:
By End User:
By Disease:
By Country:
Notable companies dominating the Asia-Pacific Tissue diagnostics Market profiled in this report are F. Hoffmann-La Roche AG, Sigma-Aldrich Co. LLC, Abbott Laboratories, Agilent Technologies, BioGenex, Danaher Corporation, Cell Signaling Technology, and Ventana Medical Systems.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product type
5.1.1 Introduction
5.1.2 Instruments
5.1.2.1 Microscope
5.1.2.2 Non-contact Handheld IR Thermometer
5.1.2.3 Haemocytometer
5.1.2.4 NMR Tube
5.1.2.5 Others
5.1.3 Consumables
5.1.3.1 Reagent kits
5.1.3.2 Others
5.1.4 Y-o-Y Growth Analysis, By Product type
5.1.5 Market Attractiveness Analysis, By Product type
5.1.6 Market Share Analysis, By Product type
5.2 Disease
5.2.1 Introduction
5.2.2 Lung cancer
5.2.3 Lymphoma
5.2.4 Pancreatic cancer
5.2.5 Breast cancer
5.2.6 Others
5.2.7 Y-o-Y Growth Analysis, By Disease
5.2.8 Market Attractiveness Analysis, By Disease
5.2.9 Market Share Analysis, By Disease
5.3 Application
5.3.1 Introduction
5.3.2 Hematoxylin and Eosin
5.3.3 Immunohistochemistry
5.3.4 In Situ Hybridization
5.3.5 Y-o-Y Growth Analysis, By Application
5.3.6 Market Attractiveness Analysis, By Application
5.3.7 Market Share Analysis, By Application
5.4 End user
5.4.1 Introduction
5.4.2 Hospitals
5.4.3 Diagnostic laboratories
5.4.4 Research Organizations
5.4.5 Contract Research Organizations
5.4.6 Biotechnology Companies
5.4.7 Y-o-Y Growth Analysis, By End user
5.4.8 Market Attractiveness Analysis, By End user
5.4.9 Market Share Analysis, By End user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product type
6.1.3.3 By Disease
6.1.3.4 By Application
6.1.3.5 By End user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product type
6.1.4.3 By disease
6.1.4.4 By Application
6.1.4.5 By End user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product type
6.1.5.3 By Disease
6.1.5.4 By Application
6.1.5.5 By End user
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 F. Hoffmann-La Roche AG
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Sigma-Aldrich Co. LLC
8.3 Abbott Laboratories
8.4 Agilent Technologies
8.5 BioGenex
8.6 Danaher Corporation
8.7 Cell Signaling Technology
8.8 Ventana Medical Systems
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
